Cencora (FRA:ABG) Total Liabilities : €57,630 Mil (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Cencora Total Liabilities?

Cencora's Total Liabilities for the quarter that ended in Mar. 2024 was €57,630 Mil.

Cencora's quarterly Total Liabilities increased from Sep. 2023 (€57,993.23 Mil) to Dec. 2023 (€58,347.83 Mil) but then declined from Dec. 2023 (€58,347.83 Mil) to Mar. 2024 (€57,629.74 Mil).

Cencora's annual Total Liabilities increased from Sep. 2021 (€48,240.39 Mil) to Sep. 2022 (€57,054.24 Mil) and increased from Sep. 2022 (€57,054.24 Mil) to Sep. 2023 (€57,993.23 Mil).

Cencora Total Liabilities Historical Data

The historical data trend for Cencora's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora Total Liabilities Chart

Cencora Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

32,850.33

38,302.18

48,240.39

57,054.24

57,993.23

Cencora Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															54,410.21	55,615.51	57,993.23	58,347.83	57,629.74

Cencora Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cencora's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45754.833	+	(3884.908	+	6799.999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1553.494	+	0)
	=	57,993

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	58617.545	-	624.311
	=	57,993

Cencora's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45780.866	+	(3845.882	+	6437.398
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1565.596	+	0)
	=	57,630

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	58758.602	-	1128.86
	=	57,630

Cencora Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cencora's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cencora (FRA:ABG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (FRA:ABG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

COR:USA C1CO34:Brazil ABC:Austria

Address

1 West First Avenue, Conshohocken, PA, USA, 19428-1800

Website

https://www.cencora.com

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.